- Home
- ENVA vs AKRO Comparison
ENVA vs AKRO Comparison
Compare ENVA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVA
- AKRO
- Stock Information
- Founded
- ENVA 2011
- AKRO 2017
- Country
- ENVA United States
- AKRO United States
- Employees
- ENVA N/A
- AKRO N/A
- Industry
- ENVA Finance: Consumer Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ENVA Finance
- AKRO Health Care
- Exchange
- ENVA Nasdaq
- AKRO Nasdaq
- Market Cap
- ENVA 2.2B
- AKRO 2.4B
- IPO Year
- ENVA N/A
- AKRO 2019
- Fundamental
- Price
- ENVA $99.91
- AKRO $30.64
- Analyst Decision
- ENVA Buy
- AKRO Strong Buy
- Analyst Count
- ENVA 7
- AKRO 8
- Target Price
- ENVA $88.00
- AKRO $46.83
- AVG Volume (30 Days)
- ENVA 214.1K
- AKRO 660.1K
- Earning Date
- ENVA 10-22-2024
- AKRO 11-08-2024
- Dividend Yield
- ENVA N/A
- AKRO N/A
- EPS Growth
- ENVA 5.61
- AKRO N/A
- EPS
- ENVA 6.23
- AKRO N/A
- Revenue
- ENVA $1,170,788,000.00
- AKRO N/A
- Revenue This Year
- ENVA N/A
- AKRO N/A
- Revenue Next Year
- ENVA $17.77
- AKRO N/A
- P/E Ratio
- ENVA $16.04
- AKRO N/A
- Revenue Growth
- ENVA 14.80
- AKRO N/A
- 52 Week Low
- ENVA $39.92
- AKRO $15.32
- 52 Week High
- ENVA $106.51
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- ENVA 63.82
- AKRO 49.43
- Support Level
- ENVA $98.25
- AKRO $27.05
- Resistance Level
- ENVA $106.51
- AKRO $35.11
- Average True Range (ATR)
- ENVA 2.73
- AKRO 1.92
- MACD
- ENVA 0.01
- AKRO -0.41
- Stochastic Oscillator
- ENVA 66.96
- AKRO 40.62
About ENVA Enova International Inc.
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and the United Kingdom. Consumers apply for credit online, receive a decision almost immediately, and can receive funds within one day. Enova acts as either the lender or a third-party facilitator between borrowers and other lenders. The company earns revenue from interest income, finance charges, and other fees, including fees on the transactions between borrowers and third-party lenders. The majority of revenue comes from the United States. The company realizes similar amounts of revenue from each of its three different products: short-term loans, lines of credit, and installment loans.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.